RBC Capital Mkts Rating Update on Colliers International Group Inc

RBC Capital Mkts has issued rating on Colliers International Group Inc in the latest move. The shares are Downgraded by RBC Capital Mkts to ” Sector Perform” and the firm has also confirmed the drop in Target Price to $ 47 from an earlier Target Price of $54 , in a research note released to the investors . The firm had an earlier rating of “Outperform ” on Colliers International Group Inc. The rating information was released on Feb 1, 2016 by RBC Capital Mkts.

Currently the company Insiders own 15.3% of Colliers International Group Inc shares according to the proxy statements.Institutional Investors own 54.55% of Colliers International Group Inc shares.

Colliers International Group Inc. is engaged in commercial real estate services with more than 16,300 professionals operating from 502 offices in 67 countries. Colliers professionals provide a range of services to real estate occupiers, owners and investors worldwide. Services include brokerage, global corporate solutions, investment sales and capital markets, project management and workplace solutions, property and asset management, consulting, valuation and appraisal services, and customized research and thought leadership.

Zacks Rating on Myriad Genetics, Inc. (NASDAQ:MYGN)

Myriad Genetics, Inc. (NASDAQ:MYGN) has received a hold rating for the short term, according to the latest rank of 3 from research firm, Zacks Investment Research. The company received an average rating of 2.33 from 13 analysts. 2 analyst have rated it as strong sell. 6 have rated it as a strong buy. 5 analysts have rated the company at hold.

Wall Street Analysts have advised their investors on the company shares.Myriad Genetics, Inc. was Initiated by Deutsche Bank on Jan 7, 2016 to Buy, Price Target of the shares are set at $52.Company shares were Reiterated by Barclays on Jan 7, 2016 to Overweight, Raises Price Target to $ 52 from a previous price target of $50 .Myriad Genetics, Inc. was Upgraded by Goldman to Neutral on Dec 8, 2015.

Myriad Genetics, Inc. Last issued its quarterly earnings results on Nov 3, 2015. The company reported $0.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.06. Analyst had a consensus of $0.35. The company had revenue of $183.50 million for the quarter, compared to analysts expectations of $177.94 million. The companys revenue was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.25 EPS.

Company has reported several Insider transactions to the SEC, on Dec 14, 2015, Walter Phd Gilbert (director) sold 5,000 shares at 42.23 per share price.On Dec 9, 2015, S. Louise Phanstiel (director) sold 5,000 shares at 44.00 per share price.On Nov 5, 2015, Heinrich Dreismann (director) sold 60,000 shares at 44.44 per share price.

Currently the company Insiders own 5.8% of Myriad Genetics, Inc. shares according to the proxy statements. In the past twelve weeks, the net percent change held by


company insiders has changed by -28.57% . During last six month period, the net percent change held by insiders has seen a change of -10.97%.

Myriad Genetics, Inc. (NASDAQ:MYGN) should head towards $41 per share according to 11 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $25 per share. The higher price estimate target is at $52 according to the Analysts.

Myriad Genetics, Inc. has lost 3.22% in the last five trading days and dropped 10.96% in the last 4 weeks. Myriad Genetics, Inc. has dropped 4.81% during the last 3-month period . Year-to-Date the stock performance stands at -10.96%.

Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. Myriad operates through two segments: diagnostics, which provides testing and collaborative development of testing that is designed to assess an individuals risk for developing disease later in life, identify a patients likelihood of responding to drug therapy and guide a patients dosing, or assess a patients risk of disease progression and disease recurrence, and other, which provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients. It offers diagnostic tests for various diseases, such as myRisk Hereditary Cancer test for hereditary cancers; myPlan Lung Cancer test for lung cancer; myPath Melanoma test for melanoma; Prolaris test for prostate cancer, and Vectra DA for rheumatoid arthritis.